{"filing":{"accession_number":"0001437749-26-027165","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"mnpr20260811_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/mnpr20260811_8k.htm"},"events":[{"id":27101,"run_id":24675,"accession_number":"0001437749-26-027165","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Monopar's second quarter 2026 financial results, including net loss of $5.3 million (vs. $2.5 million in Q2 2025), R\u0026D and G\u0026A expenses, cash position of $134.3 million, and interest income. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and material business updates regarding ALXN1840's NDA rolling submission and regulatory progress.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28487,"accession_number":"0001437749-26-027165","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Monopar's second quarter 2026 financial results, including net loss of $5.3 million (vs. $2.5 million in Q2 2025), R\u0026D and G\u0026A expenses, cash position of $134.3 million, and interest income. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and material business updates regarding ALXN1840's NDA rolling submission and regulatory progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T13:31:28.937468+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28487,"accession_number":"0001437749-26-027165","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Monopar's second quarter 2026 financial results, including net loss of $5.3 million (vs. $2.5 million in Q2 2025), R\u0026D and G\u0026A expenses, cash position of $134.3 million, and interest income. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and material business updates regarding ALXN1840's NDA rolling submission and regulatory progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T13:31:28.937468+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-08-12"}]}